6:01 PM
 | 
Dec 14, 2011
 |  BC Extra  |  Company News

Salix forges ahead with crofelemer NDA despite deal termination

Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) submitted an NDA to FDA for crofelemer to treat HIV-associated diarrhea. The submission comes just a month after Napo Pharmaceuticals Inc. (San Francisco, Calif.) said it terminated a 2008 deal that gave Salix...

Read the full 177 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >